Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SCN1A | P35498 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21788901 | 0.82 | LMNA (0.42) | TSHRTDP1ALDH1A1HSD17B10ADRB2 | |
| SCHEMBL16148176 | 0.80 | TSHR (0.38) | TSHRTDP1ALDH1A1HSD17B10ADRB2 | |
| SCHEMBL21777924 | 0.74 | LMNA (0.44) | TSHRTDP1ALDH1A1HSD17B10MAPK1 | |
| SCHEMBL21789030 | 0.72 | HCRTR2 (0.34) | ALDH1A1CYP1A2CYP2C19GAAAVPR1A | |
| SCHEMBL8447329 | 0.72 | CHRNB2 (0.41) | TDP1ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL28498515 | 0.72 | MAPK1 (0.50) | TSHRTDP1ALDH1A1HSD17B10ADRB2 | |
| SCHEMBL21830040 | 0.71 | CYP4F2 (0.33) | — | |
| SCHEMBL7557304 | 0.69 | TDP1 (0.52) | TSHRTDP1ALDH1A1HSD17B10ADRB2 | |
| SCHEMBL25893279 | 0.69 | TDP1 (0.65) | TSHRTDP1ADRB2ADRB1ADRB3 | |
| SCHEMBL1712501 | 0.68 | NPC1 (0.45) | TSHRTDP1ALDH1A1MAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2025-09-04 | — | — | US | disclosed |
| US-12275741-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2024-11-07 | — | — | US | disclosed |
| US-11952381-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2023-03-23 | — | — | US | disclosed |
| US-11414424-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-11414424-B2 | Cardiac sarcomere inhibitors | CYTOKINETICS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| EP-3843842-A1 | CARDIAC SARCOMERE INHIBITORS | Cytokinetics, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2020-04-09 | — | — | US | disclosed |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. | 2020-04-09 | — | — | US | disclosed |
| WO-2020047447-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
| WO-2020047447-A1 | CARDIAC SARCOMERE INHIBITORS | CYTOKINETICS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414424-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | TSHR 1926/4885TDP1 1194/4885ALDH1A1 3517/4885 |
| US-20200109148-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | TSHR 1926/4885TDP1 1194/4885ALDH1A1 3517/4885 |
| US-20230090256-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | TSHR 1926/4885TDP1 1194/4885ALDH1A1 3517/4885 |
| US-12275741-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | TSHR 1926/4885TDP1 1194/4885ALDH1A1 3517/4885 |
| US-20240368172-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | TSHR 1926/4885TDP1 1194/4885ALDH1A1 3517/4885 |
| US-20250276976-A1 | CARDIAC SARCOMERE INHIBITORS | TNNI3, MYLK2, TNNT2 | TSHR 1926/4885TDP1 1194/4885ALDH1A1 3517/4885 |
| US-11952381-B2 | Cardiac sarcomere inhibitors | TNNI3, MYLK2, TNNT2 | TSHR 1926/4885TDP1 1194/4885ALDH1A1 3517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.